SidaGhanaV1, PubMed, Checkpoint, bibRecord, 000819

Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.

Identifieur interne : 000819 ( PubMed/Checkpoint ); précédent : 000818; suivant : 000820

Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.

Auteurs : N K Ayisi [Ghana]

Source :

East African medical journal [ 0012-835X ] ; 1995.

RBID : pubmed:8904046

Descripteurs français

English descriptors

KwdEn :
- Antiviral Agents (pharmacology), Cytopathogenic Effect, Viral (drug effects), Didanosine (pharmacology), Drug Evaluation, Preclinical, Ghana, HIV-1 (classification), HIV-1 (drug effects), HIV-1 (pathogenicity), HIV-2 (classification), HIV-2 (drug effects), HIV-2 (pathogenicity), Humans, Microbial Sensitivity Tests, Virus Cultivation, Zalcitabine (pharmacology).
MESH :
- chemical , pharmacology : Antiviral Agents, Didanosine, Zalcitabine.
- geographic : Ghana.
- classification : HIV-1, HIV-2.
- drug effects : Cytopathogenic Effect, Viral, HIV-1, HIV-2.
- pathogenicity : HIV-1, HIV-2.
- Drug Evaluation, Preclinical, Humans, Microbial Sensitivity Tests, Virus Cultivation.

Abstract

The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.

PubMed: 8904046

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000697
to stream PubMed, to step Curation: 000697

Links to Exploration step

pubmed:8904046

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</title>
<author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name>
<affiliation wicri:level="4"><nlm:affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</nlm:affiliation>
<orgName type="university">Université du Ghana</orgName>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1995">1995</date>
<idno type="RBID">pubmed:8904046</idno>
<idno type="pmid">8904046</idno>
<idno type="wicri:Area/PubMed/Corpus">000697</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000697</idno>
<idno type="wicri:Area/PubMed/Curation">000697</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000697</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000697</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000697</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</title>
<author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name>
<affiliation wicri:level="4"><nlm:affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</nlm:affiliation>
<orgName type="university">Université du Ghana</orgName>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">East African medical journal</title>
<idno type="ISSN">0012-835X</idno>
<imprint><date when="1995" type="published">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Cytopathogenic Effect, Viral (drug effects)</term>
<term>Didanosine (pharmacology)</term>
<term>Drug Evaluation, Preclinical</term>
<term>Ghana</term>
<term>HIV-1 (classification)</term>
<term>HIV-1 (drug effects)</term>
<term>HIV-1 (pathogenicity)</term>
<term>HIV-2 (classification)</term>
<term>HIV-2 (drug effects)</term>
<term>HIV-2 (pathogenicity)</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
<term>Virus Cultivation</term>
<term>Zalcitabine (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term>
<term>Culture virale</term>
<term>Didéoxyinosine (pharmacologie)</term>
<term>Effet cytopathogène viral ()</term>
<term>Ghana</term>
<term>Humains</term>
<term>Tests de sensibilité microbienne</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité)</term>
<term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) ()</term>
<term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (pathogénicité)</term>
<term>Zalcitabine (pharmacologie)</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Didanosine</term>
<term>Zalcitabine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>HIV-1</term>
<term>HIV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term>
<term>HIV-1</term>
<term>HIV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>HIV-1</term>
<term>HIV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Didéoxyinosine</term>
<term>Zalcitabine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
<term>Virus Cultivation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Culture virale</term>
<term>Effet cytopathogène viral</term>
<term>Ghana</term>
<term>Humains</term>
<term>Tests de sensibilité microbienne</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8904046</PMID>
<DateCreated><Year>1997</Year>
<Month>02</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>1997</Year>
<Month>02</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-835X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>72</Volume>
<Issue>10</Issue>
<PubDate><Year>1995</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>East African medical journal</Title>
<ISOAbbreviation>East Afr Med J</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</ArticleTitle>
<Pagination><MedlinePgn>654-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayisi</LastName>
<ForeName>N K</ForeName>
<Initials>NK</Initials>
<AffiliationInfo><Affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Kenya</Country>
<MedlineTA>East Afr Med J</MedlineTA>
<NlmUniqueID>0372766</NlmUniqueID>
<ISSNLinking>0012-835X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6L3XT8CB3I</RegistryNumber>
<NameOfSubstance UI="D016047">Zalcitabine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>K3GDH6OH08</RegistryNumber>
<NameOfSubstance UI="D016049">Didanosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016049" MajorTopicYN="N">Didanosine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015498" MajorTopicYN="N">HIV-2</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016047" MajorTopicYN="N">Zalcitabine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year>
<Month>10</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1995</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1995</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8904046</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Ghana</li>
</country>
<region><li>Région du Grand Accra</li>
</region>
<settlement><li>Accra</li>
<li>Legon (Ghana)</li>
</settlement>
<orgName><li>Université du Ghana</li>
</orgName>
</list>
<tree><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000819 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000819 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:8904046
   |texte=   Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:8904046" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaGhanaV1

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.

Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki